UAV Corp and Genetic Networks Announce Strategic Collaboration to Combat Biohazards with Cutting-Edge Technology
UAV Corp (OTC: UMAV) and Genetic Networks have signed a Memorandum of Understanding (MOU) on April 07, 2025, forming a strategic partnership to develop solutions for detecting and countering biohazards. The collaboration will integrate 'sniffer' technologies into UMAV's airships and drones for real-time detection of nuclear, chemical, and biological hazards.
The two-year partnership combines UMAV's aerial systems with Genetic Networks' GeneScape™ platform and drug development capabilities. Key initiatives include:
- Integration of detection systems into UAV platforms
- Development of aerial-delivered countermeasures against threats
- Potential exclusive distribution partnership
- Joint R&D combining genome analysis with UAV expertise
Initial testing will be conducted on UMAV's airship at its Wewahitchka facility. Both companies currently hold Department of Defense (DoD) contracts and will support each other's government initiatives. While the MOU is non-binding, specific projects and funding will be formalized through subsequent agreements.
UAV Corp (OTC: UMAV) e Genetic Networks hanno firmato un Memorandum of Understanding (MOU) il 7 aprile 2025, formando una partnership strategica per sviluppare soluzioni per la rilevazione e il contrasto dei biohazard. La collaborazione integrerà tecnologie 'sniffer' nei dirigibili e nei droni di UMAV per la rilevazione in tempo reale di pericoli nucleari, chimici e biologici.
La partnership biennale combina i sistemi aerei di UMAV con la piattaforma GeneScape™ di Genetic Networks e le capacità di sviluppo di farmaci. Le iniziative chiave includono:
- Integrazione dei sistemi di rilevamento nelle piattaforme UAV
- Sviluppo di contromisure aeree contro le minacce
- Possibile partnership esclusiva per la distribuzione
- Ricerca e sviluppo congiunti che combinano l'analisi del genoma con l'esperienza UAV
I test iniziali saranno condotti sul dirigibile di UMAV presso il suo stabilimento di Wewahitchka. Entrambe le aziende attualmente detengono contratti con il Dipartimento della Difesa (DoD) e supporteranno le iniziative governative reciproche. Sebbene il MOU non sia vincolante, progetti specifici e finanziamenti saranno formalizzati attraverso successivi accordi.
UAV Corp (OTC: UMAV) y Genetic Networks han firmado un Memorando de Entendimiento (MOU) el 7 de abril de 2025, formando una asociación estratégica para desarrollar soluciones para la detección y contrarresto de bioamenazas. La colaboración integrará tecnologías 'sniffer' en los dirigibles y drones de UMAV para la detección en tiempo real de peligros nucleares, químicos y biológicos.
La asociación de dos años combina los sistemas aéreos de UMAV con la plataforma GeneScape™ de Genetic Networks y sus capacidades de desarrollo de medicamentos. Las iniciativas clave incluyen:
- Integración de sistemas de detección en plataformas UAV
- Desarrollo de contramedidas aéreas contra amenazas
- Posible asociación exclusiva de distribución
- I+D conjunta combinando análisis genómico con experiencia en UAV
Las pruebas iniciales se llevarán a cabo en el dirigible de UMAV en sus instalaciones de Wewahitchka. Ambas empresas actualmente tienen contratos con el Departamento de Defensa (DoD) y apoyarán las iniciativas gubernamentales de cada una. Aunque el MOU no es vinculante, proyectos específicos y financiamiento se formalizarán a través de acuerdos posteriores.
UAV Corp (OTC: UMAV)와 Genetic Networks는 2025년 4월 7일 생물 위협 탐지 및 대응 솔루션 개발을 위한 전략적 파트너십을 형성하기 위해 양해각서(MOU)를 체결했습니다. 이 협력은 UMAV의 비행선과 드론에 '스니퍼' 기술을 통합하여 핵, 화학 및 생물학적 위험을 실시간으로 탐지합니다.
2년간의 파트너십은 UMAV의 항공 시스템과 Genetic Networks의 GeneScape™ 플랫폼 및 약물 개발 능력을 결합합니다. 주요 이니셔티브는 다음과 같습니다:
- UAV 플랫폼에 탐지 시스템 통합
- 위협에 대한 항공 전달형 대응 조치 개발
- 잠재적 독점 유통 파트너십
- UAV 전문성과 유전체 분석을 결합한 공동 연구 및 개발
초기 테스트는 UMAV의 Wewahitchka 시설에 있는 비행선에서 수행됩니다. 두 회사는 현재 국방부(DoD) 계약을 보유하고 있으며 서로의 정부 이니셔티브를 지원할 것입니다. MOU는 구속력이 없지만 특정 프로젝트와 자금은 이후의 계약을 통해 공식화될 것입니다.
UAV Corp (OTC: UMAV) et Genetic Networks ont signé un protocole d'accord (MOU) le 7 avril 2025, formant un partenariat stratégique pour développer des solutions de détection et de lutte contre les biohazards. La collaboration intégrera des technologies 'sniffer' dans les dirigeables et drones de UMAV pour la détection en temps réel des dangers nucléaires, chimiques et biologiques.
Ce partenariat de deux ans combine les systèmes aériens de UMAV avec la plateforme GeneScape™ de Genetic Networks et ses capacités de développement de médicaments. Les initiatives clés comprennent:
- Intégration des systèmes de détection dans les plateformes UAV
- Développement de contre-mesures aériennes contre les menaces
- Partenariat de distribution exclusif potentiel
- Recherche et développement conjointe combinant l'analyse du génome avec l'expertise UAV
Les tests initiaux seront réalisés sur le dirigeable de UMAV dans ses installations de Wewahitchka. Les deux entreprises détiennent actuellement des contrats avec le Département de la Défense (DoD) et soutiendront les initiatives gouvernementales de l'autre. Bien que le MOU ne soit pas contraignant, des projets spécifiques et un financement seront formalisés par des accords ultérieurs.
UAV Corp (OTC: UMAV) und Genetic Networks haben am 7. April 2025 ein Memorandum of Understanding (MOU) unterzeichnet, um eine strategische Partnerschaft zur Entwicklung von Lösungen zur Erkennung und Bekämpfung von Biohazards zu bilden. Die Zusammenarbeit wird 'Sniffer'-Technologien in die Luftschiffe und Drohnen von UMAV integrieren, um nukleare, chemische und biologische Gefahren in Echtzeit zu erkennen.
Die zweijährige Partnerschaft kombiniert die Luftfahrtsysteme von UMAV mit der GeneScape™-Plattform von Genetic Networks und deren Fähigkeiten zur Arzneimittelentwicklung. Zu den wichtigsten Initiativen gehören:
- Integration von Erkennungssystemen in UAV-Plattformen
- Entwicklung von Luftliefermaßnahmen gegen Bedrohungen
- Potenzielle exklusive Vertriebspartnerschaft
- Gemeinsame Forschung und Entwicklung, die Genomanalysen mit UAV-Expertise kombiniert
Die ersten Tests werden an dem Luftschiff von UMAV in dessen Einrichtung in Wewahitchka durchgeführt. Beide Unternehmen halten derzeit Verträge mit dem Verteidigungsministerium (DoD) und unterstützen die Regierungsinitiativen des jeweils anderen. Obwohl das MOU nicht bindend ist, werden spezifische Projekte und Finanzierungen durch nachfolgende Vereinbarungen formalisiert.
- Strategic partnership enhances UMAV's product offering with biohazard detection capabilities
- Access to Genetic Networks' 4,000 generic formulations network
- Potential for new DoD contract opportunities through mutual support
- Expansion into biohazard countermeasures market
- MOU is non-binding with no guaranteed financial outcomes
- Specific project details and funding arrangements still pending
- Implementation timeline for testing not yet determined
Genetic Networks Signs MOU with UMAV
WEWAHITCHKA, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- UAV Corp (OTC: UMAV), a leader in unmanned aerial vehicle (UAV) technology, and Genetic Networks, a wholly owned subsidiary of Fifty 1 Labs, Inc. (OTC: FITY) and a pioneer in genetic perturbation and drug discovery, are excited to announce the signing of a Memorandum of Understanding (MOU) on April 07, 2025. This strategic partnership aims to develop innovative solutions for detecting and countering biohazards, contaminants, and related threats, leveraging UAV Corp’s advanced aerial systems and Genetic Networks’ proprietary GeneScape™ platform to enhance public safety, health, and security globally.
The collaboration integrates state-of-the-art “sniffer” technologies into UAV Corp’s airships and drones, enabling real-time detection of nuclear, chemical, and biological hazards. Genetic Networks, under the umbrella of Fifty 1 Labs, Inc. (OTC: FITY), contributes its expertise in biohazard identification and drug development—including a patented compound with potential broad-spectrum efficacy against infections—to create countermeasures deployable via UAV Corp’s aerial platforms. Initial testing will occur on UAV Corp’s airship, currently under completion at its Wewahitchka facility, advancing aerial threat response capabilities.
Both companies are actively engaged in Department of Defense (DoD) contracts, positioning them to assist each other in meeting stringent government requirements. UAV Corp’s UAV expertise complements Genetic Networks’ advancements in genetic science, offering mutual support for DoD initiatives. On April 1, 2025, FITY announced a groundbreaking yeast experiment launched on SpaceX’s Fram2 mission, engineered by Dr. Corey Nislow to study resistance to microgravity and cosmic radiation—data that could inform this collaboration’s countermeasure development. Genetic Networks will facilitate introductions between their relationships and UMAV’s management team to potentially unlock new opportunities for contracts and collaborations in the defense and space sectors.
“This partnership merges cutting-edge aerial technology with genetic innovation to tackle critical global challenges,” said Michael Lawson, CEO of UAV Corp. “By equipping our UAV platforms with advanced detection systems and collaborating with Genetic Networks, we’re set to deliver rapid, impactful solutions to biohazard threats worldwide while strengthening our DoD efforts and exploring new avenues.”
Gennaro D’Urso, Founder, CEO, and Chairman of Genetic Networks, added, “Teaming up with UAV Corp amplifies the reach of our GeneScape™ platform and drug development efforts, as demonstrated by our recent SpaceX Fram2 mission experiment under Fifty 1 Labs, Inc. (OTC: FITY). Together, we’re poised to detect dangers and deploy life-saving countermeasures efficiently, utilizing our supplier network of approximately 4,000 generic formulations and supporting our shared DoD objectives.”
Key initiatives outlined in the MOU include:
- Detection Systems: Integrating sniffer technologies into UAV platforms to identify contaminants and biohazards.
- Countermeasures: Developing and distributing compounds to neutralize threats, including radiation and toxic substances, via aerial delivery.
- Distribution Partnership: Exploring Genetic Networks’ potential role as an exclusive agent for countermeasure distribution, supported by UAV Corp’s aerial capabilities.
- Joint R&D: Combining whole-genome analysis with UAV expertise to refine detection and response strategies.
The two-year collaboration, effective from the signing date, reflects both companies’ dedication to innovation and societal benefit. While the MOU serves as a non-binding framework, the parties plan to formalize specific projects and funding through subsequent agreements, with testing timelines to be detailed soon.
“We’re thrilled to launch this partnership,” Lawson and D’Urso said jointly. “It strengthens our capabilities, aligns our DoD efforts, and positions us to make a tangible impact on global health and security.”
About UAV Corp
UAV Corp (OTC: UMAV) is a global leader in unmanned aerial vehicle technology, delivering advanced solutions for security, surveillance, and aerial systems across government, defense, and commercial sectors. Headquartered in Wewahitchka, Florida, UAV Corp is committed to advancing aerial innovation.
Michael Lawson, CEO
Email: mlawson@uavcorp.net
Address: 115 County Road 381, Wewahitchka, FL 32465
Phone: 877-425-1066
Website: www.uavcorp.net
About Genetic Networks
Genetic Networks, a wholly owned subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), accelerates drug discovery and compound development through its proprietary GeneScape™ platform. The company is dedicated to advancing health solutions through genetic science and strategic partnerships
Investor Relations
877-814-4188
ir@fifty1labs.com
Website: https://geneticnetworks.com/
FAQ
What is the purpose of the UAV Corp (UMAV) and Genetic Networks partnership?
When does the UMAV-Genetic Networks collaboration agreement begin and how long will it last?
What technologies will be integrated into UMAV's aerial platforms?
Where will UMAV conduct initial testing for the biohazard detection systems?
How does the UMAV partnership relate to Department of Defense contracts?
